Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Heidelberg Pharma AG is a biotechnology company focused on developing novel cancer therapies. It specializes in a proprietary technology known as Antibody Targeted Amanitin Conjugates (ATACs), aimed at delivering potent toxins specifically to cancer cells. Founded in Germany, the company is headquartered in Ladenburg and operates primarily in the pharmaceutical sector, with a strong emphasis on research and development collaborations. Heidelberg Pharma positions itself by leveraging its unique ATAC platform, differentiating itself through targeted cancer treatment modalities. The company collaborates with pharmaceutical firms to enhance its development pipeline and commercial reach across various markets. Sources: https://www.heidelberg-pharma.com/
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Heidelberg Pharma AGAbbVie
Last price
€2.13$285.07
Currency
EUR
USD
€95M$504B
-80.57
-€0.66$3.54
0.760.28
0$6.83
02.43%
Sector
HealthHealth
Employees
3357,000
Ticker
€HPHA$ABBV
Primary listing
XETRANYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €HPHA or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.